Screening novel antiviral compounds to treat Clostridioides difficile infections
PLOS ONE · 13.12.2024 · 19 (12) · e0309624
DOI: 10.1371/journal.pone.0309624 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 13.12.2024. Verfasst von Brice J Stolz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Clostridioides difficile, Antiviral Agents, Clostridium Infections, Microbial Sensitivity Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Clostridioides difficile is a major cause of nosocomial infections, often associated with individuals who have gut dysbiosis from previous antibiotic therapies. C . difficile infections (CDI) have a high recurrence rate and impose significant financial and mortality burdens on the healthcare system. Therefore, novel anti- C . difficile drugs are urgently needed to treat and reduce the severity and recurrence of infection. In this study, we screened a library of 618 antiviral drugs to identify a potential candidate for repurposing as novel anti- C . difficile therapeutics. Following our preliminary screening, we identified 9 novel compounds that inhibited C . difficile at a concentration of 16 μM or lower. Among these, 4 antiviral compounds demonstrated the most potent anti- C . difficile activity against a panel of 15 C . difficile isolates, with minimum inhibitory concentrations (MICs) comparable to the drug of choice, vancomycin. These include rottlerin (MIC 50 = 0.25 μg/mL), α-mangostin (MIC 50 = 1 μg/mL), dryocrassin ABBA (MIC 50 = 1 μg/mL), and obefazimod (MIC 50 = 4 μg/mL). All exhibited minimal to no activity against representative members of the human gut microbiota. Interestingly, α-mangostin, a natural xanthone derived from the mangosteen fruit, exhibited strong bactericidal action, clearing a high inoculum of C . difficile in less than an hour. All other drugs exhibited bacteriostatic activity. Given their characteristics, these compounds show great promise as novel treatments for CDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
- Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
ORCID-Profile: Brice J Stolz, Ahmed A Abouelkhair, Mohamed N Seleem
Förderung
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Stolz, B. J., Abouelkhair, A. A., & Seleem, M. N. (2024). Screening novel antiviral compounds to treat Clostridioides difficile infections. PLOS ONE, 19(12), e0309624. https://doi.org/10.1371/journal.pone.0309624
Vancouver
Stolz BJ, Abouelkhair AA, Seleem MN. Screening novel antiviral compounds to treat Clostridioides difficile infections. PLOS ONE. 2024;19(12):e0309624. doi:10.1371/journal.pone.0309624
BibTeX
@article{Stolz2024,
author = {Stolz, Brice J and Abouelkhair, Ahmed A and Seleem, Mohamed N},
title = {Screening novel antiviral compounds to treat Clostridioides difficile infections},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {12},
pages = {e0309624},
doi = {10.1371/journal.pone.0309624}
}
EUVIMED